Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management

Publisher： Karger

E-ISSN： 1421-9735|29|1|1-12

ISSN： 0253-5068

Source： Blood Purification, Vol.29, Iss.1, 2009-10, pp. : 1-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients

By  

Nephron Extra, Vol. 1, Iss. 1, 2011-11 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Anemia Management in the China Dialysis Outcomes and Practice Patterns Study

By  

Blood Purification, Vol. 42, Iss. 1, 2016-03 ,pp. : 33-43

Karger

Access to resources Recommend Favorite

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

By  

Cardiorenal Medicine, Vol. 7, Iss. 3, 2017-04 ,pp. : 188-197

Karger

Access to resources Recommend Favorite

Trends in Anemia Management in Hemodialysis Patients with Cancer

By  

American Journal of Nephrology, Vol. 42, Iss. 3, 2015-0 ,pp. : 206-215

Karger

Access to resources Recommend Favorite

Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients

By  

Nephron, Vol. 131, Iss. 2, 2015-0 ,pp. : 123-130

Karger

Access to resources Recommend Favorite